Logo

Millenium Pharma to Evaluate Horizon Discovery's Human and Mutant Cell Lines

Sep 15, 2008
NEW YORK (GenomeWeb News) – Horizon Discovery said today that Millenium Pharmaceuticals will evaluate seven of Horizon’s X-MAN normal and mutant isogenic cell lines during an eight-month period.
 
The X-MAN cell lines may help speed the discovery of personalized cancer medicine, the company said. These cell lines are genetically defined in vitro models of human cancer and their matched normal cell types. They include a set of double cancer-gene "knock-in" lines designed to evaluate patient resistance to targeted agents.
 
The lines Millenium is studying are model genotypes, and the drug developer will use them to characterize and test known targeted agents and internally developed compounds.
 
Horizon said Millenium will pay it a “six-figure fee and share key data sets during the course of the evaluation” beginning in October. Further terms of the agreement were not disclosed.

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.